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Anthracycline antibiotics (such as doxorubicin or daunorubicin) are antineoplastics which 
act as the topoisomerase II poisons. They stabilize a reaction intermediate in which DNA strands are 
cut  and  covalently  linked  to  tyrosine  residues  of  topoisomerase  II,  eventually  impeding  DNA 
resealing.  Failure  of  relaxing  the  supercoiled  DNA results  in  block  of  DNA replication  and 
transcription. Doxorubicin  is  used  for  the  treatment  of  solid  tumours  as  well  as  haematologic 
malignancies, while daunorubicin can be used to treat specific types of leukaemia. Unfortunately, 
cardiotoxicity  represents  serious  side  effect  of  these  drugs.  Therefore,  combinations  of 
anthracyclines  with  cardioprotective  agent  dexrazoxane  are  sometimes  used.  The  proposed 
mechanism of dexrazoxane cardioprotective action is chelation of the iron ions which decrease the 
production  of  reactive  oxygen  species.  Dexrazoxane  is  also  a  catalytic  inhibitor  of  the 
topoisomerase II and there are doubts, whether it may compromise the antitumour effectiveness of 
the anthracyclines.
The  aim of  our  work  was  therefore  to  assess  the  effects  of  different  topoisomerase  II 
catalytic inhibitors (dexrazoxane, sobuzoxane and merbarone) on the  cytotoxicity  of athracycline 
antibiotics against proliferating cancer cells. 
 In this study, the promyelocytic leukaemia HL-60 cell line was used. The cells were treated 
with variable concentration of selected compounds or their combinations for 72 hours. The MTT 
test was used for the measurement of the cellular viability. This test is based on bioreduction of the 
thiazolyl  blue  tetrazolium bromide  by viable  cells.  To  assess  apoptosis  induction,  activities  of 
caspases 3, 8 and 9 were determined using specific chemiluminescence substrates.
Our  results  indicate  that  the  combinations  of  anthracycline  antibiotics  with  catalytic 
topoisomerase II inhibitors do not compromise their antiproliferative activities. At least an additive 
effect  of  the   two compounds  was observed and the  synergistic  effect  was  observed for  some 
concentration combinations.
